Velaglucerase alfa

Thông tin thuốc gốc
Chỉ định và Liều dùng
Gaucher disease type 1
Adult: As a long-term enzyme replacement therapy: Initially, 60 units/kg once every 2 weeks via infusion over 60 minutes. Usual dosage range: 15-60 units/kg once every 2 weeks. Dosage is individualised based on the severity of the disease and adjusted according to the achievement and maintenance of therapeutic goals. Patients on imiglucerase therapy: May initiate velaglucerase alfa 2 weeks after the last imiglucerase dose, using the same dose and frequency.
Child: ≥4 years Same as adult dose.
Hướng dẫn pha thuốc
Reconstitute a 400 units vial with 4.3 mL of sterile water for inj resulting in a 100 units/mL concentration. Gently mix; do not shake. Withdraw the appropriate volume of reconstituted solution and further dilute in 100 mL of 0.9% NaCl solution. Administer the diluted solution through an in-line low protein-binding 0.2- or 0.22-micrometre filter.
Chống chỉ định
Thận trọng
Patient with symptoms of hypersensitivity to other enzyme replacement therapies. May consider premedication with antihistamines and/or corticosteroids in patients with prior hypersensitivity reactions requiring symptomatic treatment. Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypersensitivity reactions (including anaphylaxis); infusion-related reactions, IgG antibody formation.
Cardiac disorders: Tachycardia, chest discomfort.
Eye disorders: Blurred vision.
Gastrointestinal disorders: Abdominal pain, nausea, vomiting.
General disorders and administration site conditions: Fatigue, pyrexia.
Investigations: Prolonged aPTT.
Musculoskeletal and connective tissue disorders: Back pain, arthralgia, bone pain.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.
Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria.
Vascular disorders: Hypertension, hypotension, flushing.
Chỉ số theo dõi
Monitor CBC, IgG antibodies, liver enzymes; antibodies (in patients who developed antibodies to other enzyme replacement therapies). Perform bone density studies and computed tomography (CT) scan or MRI of liver and spleen.
Tác dụng
Description: Velaglucerase alfa is a biosynthetic form of human β-glucocerebrosidase, a lysosomal enzyme that catalyses the hydrolysis of glucocerebroside to glucose and ceramide. It is used to replace the β-glucocerebrosidase enzyme that is deficient in Gaucher's disease, thereby reducing the accumulated glucocerebroside and correcting the pathophysiology of Gaucher's disease. As a result, it diminishes hepatosplenomegaly and improves thrombocytopenia, anaemia, and bone disease.
Absorption: Time to peak plasma concentration: 40-60 minutes.
Excretion: Elimination half-life: 5-12 minutes.
Bảo quản
Intact vials: Store between 2-8°C. Diluted solutions are stable for up to 24 hours when stored between 2-8°C. Do not freeze. Protect from light.
Phân loại MIMS
Các thuốc khác ảnh hưởng đến chuyển hóa
Phân loại ATC
A16AB10 - velaglucerase alfa ; Belongs to the class of enzymes. Used in the treatment of alimentary tract and metabolism problems.
Tài liệu tham khảo
Anon. Velaglucerase Alfa. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 04/08/2022.

Anon. Velaglucerase Alfa. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/08/2022.

Buckingham R (ed). Velaglucerase Alfa. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/08/2022.

Joint Formulary Committee. Velaglucerase Alfa. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 04/08/2022.

Takeda New Zealand Limited. Vpriv 400 Units Powder for Solution for Infusion data sheet 19 October 2020. Medsafe. Accessed 04/08/2022.

Vpriv 400 Units Powder for Solution for Infusion (Takeda Pharmaceuticals International AG Ireland Branch). MHRA. Accessed 04/08/2022.

Vpriv Injection, Powder, Lyophilized, for Solution (Takeda Pharmaceuticals America, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 04/08/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Velaglucerase alfa từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in